Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial
The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than ...
Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling ...
drugdeliverybusiness10d
Trinity Biotech expects to submit ‘disruptive’ next-gen CGM to FDA in 2026
(Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system.